QCL-106001 (LPA114604)

• Research type

  Research Study

• Full title

  A single dose crossover study in healthy male subjects to assess the regional absorption and bioavailabiltiy of 100mg GSK2190915A

• IRAS ID

  59968

• Contact name

  Philip Evans

• Sponsor organisation

  GlaxoSmithKilne REaearch and Development Ltd

• Eudract number

  2010-021573-36

• Research summary

  GSK2190915 is an inhibitor that affects the production of leukotrienes. Leukotrienes are molecules that produce inflammation in certain parts of the body in response to allergic or inflammatory stimuli. GSK2190915 has strong potential use in the treatment of asthma and chronic obstructive pulmonary disease (COPD).The main aim of this study is to determine how effectively GSK2190915A is absorbed into the bloodstream when administered to different areas of the gut, as well as to define the proportion of the orally administered dose absorbed.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  10/IEC01/17

• Date of REC Opinion

  24 Aug 2010

• REC opinion

  Further Information Favourable Opinion